loading...| Preferred Name | Cilostazol | |
| Synonyms |
|
|
| Definitions |
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1051 |
|
| CAS_Registry |
73963-72-1 |
|
| CHEBI_ID |
CHEBI:31401 |
|
| Chemical_Formula |
C20H27N5O2 |
|
| code |
C1051 |
|
| Contributing_Source |
FDA |
|
| definition |
A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. |
|
| FDA_UNII_Code |
N7Z035406B |
|
| in_subset | ||
| label |
Cilostazol |
|
| Legacy Concept Name |
Cilostazol |
|
| Preferred_Name |
Cilostazol |
|
| prefixIRI |
NCIT:C1051 |
|
| prefLabel |
Cilostazol |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0055729 |
|
| subClassOf |